Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Eledon Pharmaceuticals, Inc. (ELDN)

2.36   -0.21 (-8.17%) 03-24 16:00
Open: 2.48 Pre. Close: 2.57
High: 2.58 Low: 2.2913
Volume: 15,726 Market Cap: 32(M)

Technical analysis

as of: 2023-03-24 4:25:36 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 3.18     One year: 3.72
Support: Support1: 2.21    Support2: 1.89
Resistance: Resistance1: 2.73    Resistance2: 3.18
Pivot: 2.28
Moving Average: MA(5): 2.41     MA(20): 2.3
MA(100): 2.59     MA(250): 2.86
MACD: MACD(12,26): -0.1     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 76.9     %D(3): 72.2
RSI: RSI(14): 48.1
52-week: High: 4.13  Low: 1.89
Average Vol(K): 3-Month: 22 (K)  10-Days: 38 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ELDN ] has closed below upper band by 37.6%. Bollinger Bands are 0.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.58 - 2.6 2.6 - 2.61
Low: 2.26 - 2.28 2.28 - 2.29
Close: 2.34 - 2.36 2.36 - 2.38

Company Description

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Headline News

Thu, 23 Mar 2023
Eledon to Present Data from Ongoing Phase 1b Trial Evaluating ... - The Bakersfield Californian

Tue, 07 Mar 2023
Fitness Mogul Augie Nieto’s Fight Against ALS Lives On - Orange County Business Journal

Mon, 27 Feb 2023
Ameren Missouri Announces Pricing Of First Mortgage Bonds Due In ... - Kalkine Media

Wed, 08 Feb 2023
Does Eledon Pharmaceuticals Inc (ELDN) Have What it Takes to be in Your Portfolio Wednesday? - InvestorsObserver

Mon, 09 Jan 2023
eGenesis and Eledon Pharmaceuticals Announce Collaboration for ... - GlobeNewswire

Thu, 05 Jan 2023
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation - Simply Wall St

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 14 (M)
Shares Float 10 (M)
% Held by Insiders 10 (%)
% Held by Institutions 48.6 (%)
Shares Short 17 (K)
Shares Short P.Month 17 (K)

Stock Financials

EPS -2.8
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 10.26
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -15
Return on Equity (ttm) -24.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -28 (M)
Levered Free Cash Flow -14 (M)

Stock Valuations

PE Ratio -0.85
PEG Ratio 0
Price to Book value 0.23
Price to Sales 0
Price to Cash Flow -1.16

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-10-04
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.